Special Issue "The Bright and Dark Sides of Apoptosis and Other Modes of Cell “Death” in Cancer Therapy"
Deadline for manuscript submissions: 31 December 2021.
Interests: DNA damage response; p53 signaling; senescence; polyploidy; multinucleation; radioresistance; chemoresistance; Li-Fraumeni syndrome
Special Issues and Collections in MDPI journals
Special Issue in International Journal of Molecular Sciences: p53 Signaling and Cancer Cell Response to Genotoxic Stress: Beyond Cell Cycle Checkpoints and Apoptosis
Special Issue in International Journal of Molecular Sciences: The Cellular Response to DNA Damage 2.0: From DNA Repair to Polyploidy and Beyond
Stress-induced programmed cell death (e.g., through apoptosis) and “functional death” (e.g., dormancy through premature senescence) in cancer cells have long been regarded as favorable outcomes in cancer therapy. In the past decade, however, it has become evident that while these responses are essential for initial tumor control, they can also contribute to disease relapse, at least in solid tumors. Apoptotic cancer cells, for example, not only secrete tumor-promoting factors but can also undergo a reversal process (through anastasis), giving rise to tumor repopulating progeny. Reversal of a subset of apoptotic/dormant cancer cells contributes to intratumor heterogeneity, which poses a major challenge in treating cancer patients with metastatic disease. Unfortunately, intratumor heterogeneity is overlooked in most preclinical methods used in anticancer studies.
The purpose of this Special Issue is to provide a comprehensive update on molecular events that underlie intratumor heterogeneity in the context of cancer therapy. Reviews and original articles addressing the dark side of stress-induced apoptosis and senescence in solid tumors are particularly welcomed.
Prof. Dr. Razmik Mirzayans
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- intratumor heterogeneity
- single-cell analysis
- apoptosis and tumorigenicity
- cell fusion
- novel therapeutic strategies targeting dormant cancer cells